Syneos Health SYNH recently signed an agreement with Union Hospital, Tongji Medical College and the Huazhong University of Science and Technology (Wuhan Union Hospital).  This expands the company’s clinical trial capabilities across a broad range of therapeutic areas in China.

Via the agreement, Wuhan Union Hospital is now part of Syneos Health’s Catalyst Site Program. The program was introduced in 2016 to strengthen collaborations with clinical research sites worldwide.

More About the Clinical Site Program

The Syneos Health Catalyst Site Program is aimed at streamlining every aspect of the clinical development process and supporting the development of new methodologies to deliver faster therapies to patients. It harnesses insights from clinical research sites worldwide to drive continuous improvement and develop the best practices in clinical research delivery.

Image Source: Zacks Investment Research

The company has been acknowledged by the Society for Clinical Research Sites as a recipient of the Eagle Award for demonstrating dedication to establishing strong site partnerships. The Catalyst Site Network includes more than 100 high-performing sites worldwide, including individual practices, academic centers of excellence and site networks.

News in Detail

Syneos Health’s venture with Wuhan Union Hospital is part of Syneos Health’s global strategy to accelerate its clinical development impact on China’s rapidly growing and changing market. The cooperation aims to expedite study timelines and enable sites, sponsors and patients to be more engaged throughout the entire clinical trial process.

Recognizing Wuhan Union Hospital as a first-class site, management notes that the strategic collaboration will foster a stronger development of its clinical business in Central China and enhance the benefits of serving patients in this region.

Industry Prospects

Per a Research report, the global eClinical solution market was valued at $7.89 billion in 2022 and is expected to witness a CAGR of 13.9% by 2030.

Recent Highlights

The company recently expanded the Catalyst Site Program in New Zealand via an agreement with Aotearoa Clinical Trials and Optimal Clinical Trials Ltd. SYNH’s collaboration with the University Malaya Medical Centre in Malaysia leverages its deep site relationships to help customers navigate the region’s highly regulated and complex operating environment to deliver consistent quality, predictable results and streamlined processes in the clinical trial.

In June 2023, SYNH announced a collaboration with uMotif, aiming to bring new therapies to patients faster through a more efficient, end-to-end digital platform that includes robust Electronic Clinical Outcome Assessment (eCOA) and Electronic Patient-reported Outcomes (ePRO) capabilities.